We are more than happy and proud to announce that our team has been selected for the highly competitive EIC Accelerator: Out of over 1200 applicants across Europe, we are honored to be one of the innovative companies chosen in what has been described as the most competitive funding round to date. 🚀🚀🚀
Thanks to this approval, MyoPax are set to receive €2.5 million in non-dilutive grant funding with the option for an additional equity investment from the EIC fund, the EU’s venture investment arm.
This esteemed funding will significantly boost our progress toward and in the clinical development of regenerative gene repair therapies for severe muscular dystrophies.
Thank you to the European Innovation Council for believing in our mission. We are more than eager to embark on this next phase of innovation.
Being part of this selected group is a testament to our overall team’s dedication and the transformative approach.
🤝 BioInnovation Institute, Max Delbrück Center, Charité – Universitätsmedizin Berlin, & all the brilliant collaborators and supporters who have made this achievement possible:
We are determined to push the boundaries of science, medicine and drug development towards a truly transformative treatment.
🌍Here’s to making a difference💡
